G Bert---We have 200mm AS I believe---if this drug makes it to market it will easily generate $15 billion/year----we only have 50mm shares outstanding----if we had to use all of the remaining 150mm shares-----and we only use 1X earnings we would be at $75 pps------more likely we will use 100mm total shares and we will be priced at 2X earnings---$300 pps---it's all a guess this far out but we are in good shape as long as our science is solid.
It's more likely that Roche (someone?) will partner with us or buy us out before we are very far along in this process. This drug will work on 75% of breast cancer cases--HUGE!!!
Market Data 
Markets 
AI
